The Ambifect version of the new trial drug builds on Akston's anti-cPD-L1 mAb, designed to target and block the cPD-L1 protein on cancer cells, which is currently in clinical trial for dogs with ...

Akston, the Biotech Built for Pets, in partnership with Purdue University and its College of Veterinary Medicine, announced today that it has initiated a clinical study to evaluate a first–in–class ...

Mast cell tumors are prevalent skin neoplasms observed in veterinary clinical practice, particularly affecting both dogs and cats. Over the years, rigorous ...

A: A mast cell tumor, or MCT, is the most common form of skin cancer in dogs. Mast cells are white blood cells designed to fight parasites and allergies. It's not clear why some of these immune cells ...

The most common treatment is surgical removal of the MCT, which is often curative, especially for low-grade tumors that are ...

Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancer Treated With ...

Adoptive T cell therapy has transformed cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable clinical success in hematological malignancies. By genetically ...

Mast cell tumors (MCTs) are among the most common skin cancers affecting dogs and cats. These tumors originate from mast cells – immune cells that play a key role in allergic reactions and ...

In dogs, mast cell tumors are the most common malignant skin tumors, accounting for approximately 16–21% of all skin cancers. These tumors can appear anywhere on the body but are most frequently found ...